Tuesday, December 15, 2015 Presented by Ali McBride

Ali McBride, PharmD, MS, BCPS
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
This peer-delivered program, brought to you by Takeda, will include a clinical overview of NINLARO and its product attributes.
Related Items
A Review of Clinical Trials Suggesting the Use of PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on August 11, 2020 in Interview with the Innovators, Video
The Impact of Germline or Somatic HRD Testing on Treatment Decisions in Ovarian Cancer
Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on July 14, 2020 in Interview with the Innovators, Video
The Role of Genetic Testing in Patients with Ovarian Cancer
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, Ali McBride, PharmD, MS, BCPS
Videos published on June 26, 2020 in Interview with the Innovators, Video
Managing Patients on Oral Oncolytics
Ali McBride, PharmD, MS, BCPS
Conference Correspondent  published on December 7, 2015 in Conference Correspondent, ASH
Infusion-related Reactions
Ali McBride, PharmD, MS, BCPS, Nolan Ngo, PharmD, BCPS, Christopher Campen, PharmD, BCPS
TOP - May 2010 Vol 3, No 3 published on June 9, 2010
Last modified: April 27, 2020